Review
Version 1
This version is not peer-reviewed
What We Know about Nasal Polyposis: The Clinician’s Point of View
Version 1
: Received: 21 August 2024 / Approved: 22 August 2024 / Online: 22 August 2024 (14:55:16 CEST)
How to cite: Eloy, P.; Musat, G. What We Know about Nasal Polyposis: The Clinician’s Point of View. Preprints 2024, 2024081647. https://doi.org/10.20944/preprints202408.1647.v1 Eloy, P.; Musat, G. What We Know about Nasal Polyposis: The Clinician’s Point of View. Preprints 2024, 2024081647. https://doi.org/10.20944/preprints202408.1647.v1
Abstract
Nasal polyposis is defined by a Th2-driven chronic inflammation of the nose and sinus with polyps visible in the nasal fossae. It is a prevalent disease with a significant impact on the HRQL. Allergy, allergic rhinitis, asthma, and aspirin intolerance are frequently associated. The management is individual. The first line of treatment is a long-term treatment with intranasal corticosteroids. Oral corticosteroids should be used with caution. When the medical treatment fails the patient is eligible for sinus surgery. In case of symptomatic recurrence after both medical treatment and ethmoidectomy, biologics are nowadays a very promising treatment effective on all the respiratory tract. Dupilumab seems in the literature the molecule of choice. However, besides the international guidelines published by EPOS and Euforea, the molecule prescribed depends also on the availability of it in each country and the criteria edited by the health authorities to get reimbursement. Long treatment is mandatory. Traditional medical treatment is necessary as a complement to biologics.
Keywords
Nasal Polyposis
Subject
Medicine and Pharmacology, Otolaryngology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
